nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—CALM1—type 2 diabetes mellitus	0.239	0.578	CbGaD
Trifluoperazine—HTR2C—type 2 diabetes mellitus	0.0998	0.241	CbGaD
Trifluoperazine—CYP1A2—type 2 diabetes mellitus	0.0753	0.182	CbGaD
Trifluoperazine—HTR6—Bromocriptine—type 2 diabetes mellitus	0.0495	0.166	CbGbCtD
Trifluoperazine—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0288	0.0967	CbGbCtD
Trifluoperazine—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0272	0.0912	CbGbCtD
Trifluoperazine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.026	0.0872	CbGbCtD
Trifluoperazine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0249	0.0836	CbGbCtD
Trifluoperazine—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0239	0.0803	CbGbCtD
Trifluoperazine—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0207	0.0695	CbGbCtD
Trifluoperazine—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0185	0.062	CbGbCtD
Trifluoperazine—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0141	0.0473	CbGbCtD
Trifluoperazine—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0133	0.0448	CbGbCtD
Trifluoperazine—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0111	0.0372	CbGbCtD
Trifluoperazine—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.0105	0.0352	CbGbCtD
Trifluoperazine—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00917	0.0308	CbGbCtD
Trifluoperazine—CYP1A2—Losartan—type 2 diabetes mellitus	0.00714	0.024	CbGbCtD
Trifluoperazine—ABCB1—Glyburide—type 2 diabetes mellitus	0.00683	0.0229	CbGbCtD
Trifluoperazine—ABCB1—Losartan—type 2 diabetes mellitus	0.00625	0.021	CbGbCtD
Trifluoperazine—CALM1—sympathetic nervous system—type 2 diabetes mellitus	0.00234	0.0452	CbGeAlD
Trifluoperazine—HTR2A—arteriole—type 2 diabetes mellitus	0.00223	0.0432	CbGeAlD
Trifluoperazine—CALY—islet of Langerhans—type 2 diabetes mellitus	0.00173	0.0334	CbGeAlD
Trifluoperazine—CALM1—autonomic nervous system—type 2 diabetes mellitus	0.00157	0.0304	CbGeAlD
Trifluoperazine—S100A4—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.00151	0.752	CbGdCrCtD
Trifluoperazine—S100A4—islet of Langerhans—type 2 diabetes mellitus	0.00149	0.0289	CbGeAlD
Trifluoperazine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00142	0.0275	CbGeAlD
Trifluoperazine—EBPL—adipose tissue—type 2 diabetes mellitus	0.00121	0.0233	CbGeAlD
Trifluoperazine—S100A4—nephron tubule—type 2 diabetes mellitus	0.0012	0.0232	CbGeAlD
Trifluoperazine—CALM2—peripheral nervous system—type 2 diabetes mellitus	0.00114	0.022	CbGeAlD
Trifluoperazine—CALM1—peripheral nervous system—type 2 diabetes mellitus	0.00113	0.0219	CbGeAlD
Trifluoperazine—S100A4—cardiovascular system—type 2 diabetes mellitus	0.00108	0.0209	CbGeAlD
Trifluoperazine—S100A4—kidney—type 2 diabetes mellitus	0.00106	0.0204	CbGeAlD
Trifluoperazine—S100A4—pancreas—type 2 diabetes mellitus	0.00105	0.0203	CbGeAlD
Trifluoperazine—S100A4—cortex of kidney—type 2 diabetes mellitus	0.00103	0.0199	CbGeAlD
Trifluoperazine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000957	0.0185	CbGeAlD
Trifluoperazine—S100A4—adipose tissue—type 2 diabetes mellitus	0.000953	0.0184	CbGeAlD
Trifluoperazine—UGT1A4—kidney—type 2 diabetes mellitus	0.000928	0.0179	CbGeAlD
Trifluoperazine—TNNC1—cardiovascular system—type 2 diabetes mellitus	0.000909	0.0176	CbGeAlD
Trifluoperazine—CALM2—artery—type 2 diabetes mellitus	0.000895	0.0173	CbGeAlD
Trifluoperazine—CALM1—artery—type 2 diabetes mellitus	0.000891	0.0172	CbGeAlD
Trifluoperazine—CALM2—nerve—type 2 diabetes mellitus	0.000888	0.0172	CbGeAlD
Trifluoperazine—HTR2A—hindlimb—type 2 diabetes mellitus	0.000885	0.0171	CbGeAlD
Trifluoperazine—CALM1—nerve—type 2 diabetes mellitus	0.000884	0.0171	CbGeAlD
Trifluoperazine—EBPL—liver—type 2 diabetes mellitus	0.000846	0.0164	CbGeAlD
Trifluoperazine—DRD2—nerve—type 2 diabetes mellitus	0.000816	0.0158	CbGeAlD
Trifluoperazine—EBP—liver—type 2 diabetes mellitus	0.000811	0.0157	CbGeAlD
Trifluoperazine—TNNC1—adipose tissue—type 2 diabetes mellitus	0.000802	0.0155	CbGeAlD
Trifluoperazine—CALM2—endothelium—type 2 diabetes mellitus	0.000756	0.0146	CbGeAlD
Trifluoperazine—CALM1—endothelium—type 2 diabetes mellitus	0.000752	0.0145	CbGeAlD
Trifluoperazine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.00069	0.0133	CbGeAlD
Trifluoperazine—XDH—kidney—type 2 diabetes mellitus	0.000677	0.0131	CbGeAlD
Trifluoperazine—S100A4—liver—type 2 diabetes mellitus	0.000668	0.0129	CbGeAlD
Trifluoperazine—UGT1A4—liver—type 2 diabetes mellitus	0.000587	0.0113	CbGeAlD
Trifluoperazine—CALM3—islet of Langerhans—type 2 diabetes mellitus	0.000548	0.0106	CbGeAlD
Trifluoperazine—HTR2A—artery—type 2 diabetes mellitus	0.000543	0.0105	CbGeAlD
Trifluoperazine—HTR2A—nerve—type 2 diabetes mellitus	0.000538	0.0104	CbGeAlD
Trifluoperazine—EBP—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000498	0.248	CbGdCrCtD
Trifluoperazine—SIGMAR1—islet of Langerhans—type 2 diabetes mellitus	0.000489	0.00946	CbGeAlD
Trifluoperazine—CALM3—retina—type 2 diabetes mellitus	0.000468	0.00905	CbGeAlD
Trifluoperazine—HTR2A—endothelium—type 2 diabetes mellitus	0.000458	0.00886	CbGeAlD
Trifluoperazine—CALM3—nephron tubule—type 2 diabetes mellitus	0.000441	0.00852	CbGeAlD
Trifluoperazine—CALM2—islet of Langerhans—type 2 diabetes mellitus	0.00043	0.00831	CbGeAlD
Trifluoperazine—CALM1—islet of Langerhans—type 2 diabetes mellitus	0.000428	0.00827	CbGeAlD
Trifluoperazine—XDH—liver—type 2 diabetes mellitus	0.000428	0.00827	CbGeAlD
Trifluoperazine—SIGMAR1—nephron tubule—type 2 diabetes mellitus	0.000394	0.00761	CbGeAlD
Trifluoperazine—CHRM2—cardiovascular system—type 2 diabetes mellitus	0.00039	0.00754	CbGeAlD
Trifluoperazine—CALM3—pancreas—type 2 diabetes mellitus	0.000385	0.00744	CbGeAlD
Trifluoperazine—CALM3—cortex of kidney—type 2 diabetes mellitus	0.000377	0.00729	CbGeAlD
Trifluoperazine—CALM2—retina—type 2 diabetes mellitus	0.000368	0.0071	CbGeAlD
Trifluoperazine—CALM1—retina—type 2 diabetes mellitus	0.000366	0.00707	CbGeAlD
Trifluoperazine—CALM3—adipose tissue—type 2 diabetes mellitus	0.000349	0.00675	CbGeAlD
Trifluoperazine—CALM2—nephron tubule—type 2 diabetes mellitus	0.000346	0.00669	CbGeAlD
Trifluoperazine—CALM1—nephron tubule—type 2 diabetes mellitus	0.000345	0.00666	CbGeAlD
Trifluoperazine—SIGMAR1—pancreas—type 2 diabetes mellitus	0.000344	0.00665	CbGeAlD
Trifluoperazine—DRD2—retina—type 2 diabetes mellitus	0.000338	0.00653	CbGeAlD
Trifluoperazine—SIGMAR1—cortex of kidney—type 2 diabetes mellitus	0.000337	0.00652	CbGeAlD
Trifluoperazine—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000316	0.00611	CbGeAlD
Trifluoperazine—SIGMAR1—adipose tissue—type 2 diabetes mellitus	0.000312	0.00603	CbGeAlD
Trifluoperazine—CALM2—cardiovascular system—type 2 diabetes mellitus	0.000311	0.00601	CbGeAlD
Trifluoperazine—CALM1—cardiovascular system—type 2 diabetes mellitus	0.00031	0.00598	CbGeAlD
Trifluoperazine—CALM2—kidney—type 2 diabetes mellitus	0.000304	0.00588	CbGeAlD
Trifluoperazine—CALM1—kidney—type 2 diabetes mellitus	0.000303	0.00585	CbGeAlD
Trifluoperazine—CALM2—pancreas—type 2 diabetes mellitus	0.000302	0.00584	CbGeAlD
Trifluoperazine—CALM1—pancreas—type 2 diabetes mellitus	0.000301	0.00581	CbGeAlD
Trifluoperazine—CALM2—cortex of kidney—type 2 diabetes mellitus	0.000296	0.00573	CbGeAlD
Trifluoperazine—CALM1—cortex of kidney—type 2 diabetes mellitus	0.000295	0.0057	CbGeAlD
Trifluoperazine—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000292	0.00564	CbGeAlD
Trifluoperazine—CALM2—adipose tissue—type 2 diabetes mellitus	0.000274	0.0053	CbGeAlD
Trifluoperazine—CALM1—adipose tissue—type 2 diabetes mellitus	0.000273	0.00527	CbGeAlD
Trifluoperazine—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000257	0.00497	CbGeAlD
Trifluoperazine—CALM3—liver—type 2 diabetes mellitus	0.000245	0.00473	CbGeAlD
Trifluoperazine—HTR2A—retina—type 2 diabetes mellitus	0.000223	0.00431	CbGeAlD
Trifluoperazine—SIGMAR1—liver—type 2 diabetes mellitus	0.000219	0.00423	CbGeAlD
Trifluoperazine—HRH1—adipose tissue—type 2 diabetes mellitus	0.000199	0.00385	CbGeAlD
Trifluoperazine—CALM2—liver—type 2 diabetes mellitus	0.000192	0.00372	CbGeAlD
Trifluoperazine—CALM1—liver—type 2 diabetes mellitus	0.000191	0.0037	CbGeAlD
Trifluoperazine—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000189	0.00364	CbGeAlD
Trifluoperazine—HTR2A—kidney—type 2 diabetes mellitus	0.000185	0.00357	CbGeAlD
Trifluoperazine—ADRA1A—liver—type 2 diabetes mellitus	0.00018	0.00349	CbGeAlD
Trifluoperazine—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000171	0.0033	CbGeAlD
Trifluoperazine—Eosinophilia—Ramipril—type 2 diabetes mellitus	0.00015	0.0012	CcSEcCtD
Trifluoperazine—CYP1A2—liver—type 2 diabetes mellitus	0.000149	0.00288	CbGeAlD
Trifluoperazine—Rash—Repaglinide—type 2 diabetes mellitus	0.000149	0.00119	CcSEcCtD
Trifluoperazine—Bronchospasm—Ramipril—type 2 diabetes mellitus	0.000149	0.00119	CcSEcCtD
Trifluoperazine—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.000149	0.00119	CcSEcCtD
Trifluoperazine—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000149	0.00119	CcSEcCtD
Trifluoperazine—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000149	0.00119	CcSEcCtD
Trifluoperazine—Fluphenazine—CALM1—type 2 diabetes mellitus	0.000149	0.0388	CrCbGaD
Trifluoperazine—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.000148	0.00118	CcSEcCtD
Trifluoperazine—Headache—Repaglinide—type 2 diabetes mellitus	0.000148	0.00118	CcSEcCtD
Trifluoperazine—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	0.000148	0.00118	CcSEcCtD
Trifluoperazine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000148	0.00118	CcSEcCtD
Trifluoperazine—Agranulocytosis—Losartan—type 2 diabetes mellitus	0.000147	0.00117	CcSEcCtD
Trifluoperazine—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000147	0.00117	CcSEcCtD
Trifluoperazine—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000146	0.00117	CcSEcCtD
Trifluoperazine—Muscle spasms—Valsartan—type 2 diabetes mellitus	0.000146	0.00117	CcSEcCtD
Trifluoperazine—ABCB1—retina—type 2 diabetes mellitus	0.000146	0.00282	CbGeAlD
Trifluoperazine—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000145	0.00116	CcSEcCtD
Trifluoperazine—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.000145	0.00115	CcSEcCtD
Trifluoperazine—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000145	0.00115	CcSEcCtD
Trifluoperazine—Cough—Gliclazide—type 2 diabetes mellitus	0.000145	0.00115	CcSEcCtD
Trifluoperazine—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000144	0.00115	CcSEcCtD
Trifluoperazine—Pancytopenia—Ramipril—type 2 diabetes mellitus	0.000144	0.00115	CcSEcCtD
Trifluoperazine—Convulsion—Gliclazide—type 2 diabetes mellitus	0.000144	0.00115	CcSEcCtD
Trifluoperazine—Anorexia—Glyburide—type 2 diabetes mellitus	0.000144	0.00115	CcSEcCtD
Trifluoperazine—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000143	0.00115	CcSEcCtD
Trifluoperazine—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000143	0.00114	CcSEcCtD
Trifluoperazine—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000142	0.00113	CcSEcCtD
Trifluoperazine—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000142	0.00113	CcSEcCtD
Trifluoperazine—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000141	0.00113	CcSEcCtD
Trifluoperazine—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000141	0.00112	CcSEcCtD
Trifluoperazine—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000141	0.00112	CcSEcCtD
Trifluoperazine—Hypotension—Glyburide—type 2 diabetes mellitus	0.000141	0.00112	CcSEcCtD
Trifluoperazine—Nausea—Repaglinide—type 2 diabetes mellitus	0.00014	0.00112	CcSEcCtD
Trifluoperazine—Asthenia—Glipizide—type 2 diabetes mellitus	0.00014	0.00112	CcSEcCtD
Trifluoperazine—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00014	0.00112	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	0.00014	0.00111	CcSEcCtD
Trifluoperazine—Angioedema—Valsartan—type 2 diabetes mellitus	0.000139	0.00111	CcSEcCtD
Trifluoperazine—Erythema—Metformin—type 2 diabetes mellitus	0.000139	0.00111	CcSEcCtD
Trifluoperazine—Pruritus—Glipizide—type 2 diabetes mellitus	0.000138	0.00111	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Ramipril—type 2 diabetes mellitus	0.000138	0.0011	CcSEcCtD
Trifluoperazine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000138	0.0011	CcSEcCtD
Trifluoperazine—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000138	0.0011	CcSEcCtD
Trifluoperazine—Weight increased—Ramipril—type 2 diabetes mellitus	0.000138	0.0011	CcSEcCtD
Trifluoperazine—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000138	0.00266	CbGeAlD
Trifluoperazine—Angioedema—Orlistat—type 2 diabetes mellitus	0.000137	0.0011	CcSEcCtD
Trifluoperazine—Antrafenine—PTGS2—type 2 diabetes mellitus	0.000137	0.0357	CrCbGaD
Trifluoperazine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000135	0.00107	CcSEcCtD
Trifluoperazine—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000135	0.00107	CcSEcCtD
Trifluoperazine—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000134	0.00107	CcSEcCtD
Trifluoperazine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000134	0.00107	CcSEcCtD
Trifluoperazine—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000133	0.00106	CcSEcCtD
Trifluoperazine—Cough—Valsartan—type 2 diabetes mellitus	0.000133	0.00106	CcSEcCtD
Trifluoperazine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000133	0.00106	CcSEcCtD
Trifluoperazine—Jaundice—Ramipril—type 2 diabetes mellitus	0.000132	0.00105	CcSEcCtD
Trifluoperazine—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000131	0.00105	CcSEcCtD
Trifluoperazine—Cough—Orlistat—type 2 diabetes mellitus	0.000131	0.00105	CcSEcCtD
Trifluoperazine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000131	0.00105	CcSEcCtD
Trifluoperazine—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000131	0.00105	CcSEcCtD
Trifluoperazine—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000131	0.00104	CcSEcCtD
Trifluoperazine—Erythema—Irbesartan—type 2 diabetes mellitus	0.000131	0.00104	CcSEcCtD
Trifluoperazine—Vision blurred—Metformin—type 2 diabetes mellitus	0.000131	0.00104	CcSEcCtD
Trifluoperazine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000131	0.00104	CcSEcCtD
Trifluoperazine—Convulsion—Orlistat—type 2 diabetes mellitus	0.00013	0.00104	CcSEcCtD
Trifluoperazine—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.00013	0.00104	CcSEcCtD
Trifluoperazine—Tremor—Metformin—type 2 diabetes mellitus	0.00013	0.00104	CcSEcCtD
Trifluoperazine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000129	0.00103	CcSEcCtD
Trifluoperazine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000129	0.00103	CcSEcCtD
Trifluoperazine—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000127	0.00101	CcSEcCtD
Trifluoperazine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000127	0.00101	CcSEcCtD
Trifluoperazine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Trifluoperazine—Agranulocytosis—Ramipril—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Trifluoperazine—Propericiazine—ADRA2A—type 2 diabetes mellitus	0.000126	0.0329	CrCbGaD
Trifluoperazine—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000126	0.001	CcSEcCtD
Trifluoperazine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000125	0.001	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000124	0.000992	CcSEcCtD
Trifluoperazine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000124	0.00099	CcSEcCtD
Trifluoperazine—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000124	0.00239	CbGeAlD
Trifluoperazine—Rash—Glipizide—type 2 diabetes mellitus	0.000123	0.000985	CcSEcCtD
Trifluoperazine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000123	0.000984	CcSEcCtD
Trifluoperazine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000123	0.000984	CcSEcCtD
Trifluoperazine—Erythema—Losartan—type 2 diabetes mellitus	0.000123	0.000983	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000123	0.00098	CcSEcCtD
Trifluoperazine—Headache—Glipizide—type 2 diabetes mellitus	0.000123	0.000979	CcSEcCtD
Trifluoperazine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000123	0.000979	CcSEcCtD
Trifluoperazine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000122	0.000977	CcSEcCtD
Trifluoperazine—ABCB1—kidney—type 2 diabetes mellitus	0.000121	0.00234	CbGeAlD
Trifluoperazine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000121	0.000964	CcSEcCtD
Trifluoperazine—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000121	0.000964	CcSEcCtD
Trifluoperazine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000121	0.000963	CcSEcCtD
Trifluoperazine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00012	0.000961	CcSEcCtD
Trifluoperazine—Promethazine—CALM1—type 2 diabetes mellitus	0.00012	0.0315	CrCbGaD
Trifluoperazine—Agitation—Irbesartan—type 2 diabetes mellitus	0.00012	0.00096	CcSEcCtD
Trifluoperazine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.00012	0.00096	CcSEcCtD
Trifluoperazine—ABCB1—pancreas—type 2 diabetes mellitus	0.00012	0.00232	CbGeAlD
Trifluoperazine—Urticaria—Glyburide—type 2 diabetes mellitus	0.00012	0.000955	CcSEcCtD
Trifluoperazine—Nervousness—Losartan—type 2 diabetes mellitus	0.00012	0.000955	CcSEcCtD
Trifluoperazine—Angioedema—Irbesartan—type 2 diabetes mellitus	0.00012	0.000954	CcSEcCtD
Trifluoperazine—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000119	0.000954	CcSEcCtD
Trifluoperazine—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000119	0.000952	CcSEcCtD
Trifluoperazine—Anorexia—Valsartan—type 2 diabetes mellitus	0.000118	0.000946	CcSEcCtD
Trifluoperazine—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000118	0.000945	CcSEcCtD
Trifluoperazine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000118	0.000944	CcSEcCtD
Trifluoperazine—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000118	0.00228	CbGeAlD
Trifluoperazine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000117	0.000938	CcSEcCtD
Trifluoperazine—Perphenazine—CALM1—type 2 diabetes mellitus	0.000117	0.0307	CrCbGaD
Trifluoperazine—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000117	0.000935	CcSEcCtD
Trifluoperazine—HTR2A—liver—type 2 diabetes mellitus	0.000117	0.00225	CbGeAlD
Trifluoperazine—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000117	0.000931	CcSEcCtD
Trifluoperazine—Nausea—Glipizide—type 2 diabetes mellitus	0.000116	0.000928	CcSEcCtD
Trifluoperazine—Hypotension—Valsartan—type 2 diabetes mellitus	0.000116	0.000927	CcSEcCtD
Trifluoperazine—Vision blurred—Losartan—type 2 diabetes mellitus	0.000116	0.000926	CcSEcCtD
Trifluoperazine—Cyamemazine—HTR2C—type 2 diabetes mellitus	0.000116	0.0303	CrCbGaD
Trifluoperazine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000116	0.000923	CcSEcCtD
Trifluoperazine—Tremor—Losartan—type 2 diabetes mellitus	0.000115	0.000921	CcSEcCtD
Trifluoperazine—Rash—Glimepiride—type 2 diabetes mellitus	0.000115	0.000919	CcSEcCtD
Trifluoperazine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000115	0.000918	CcSEcCtD
Trifluoperazine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000115	0.000916	CcSEcCtD
Trifluoperazine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000115	0.000916	CcSEcCtD
Trifluoperazine—Headache—Glimepiride—type 2 diabetes mellitus	0.000114	0.000913	CcSEcCtD
Trifluoperazine—Cough—Irbesartan—type 2 diabetes mellitus	0.000114	0.000912	CcSEcCtD
Trifluoperazine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000114	0.000911	CcSEcCtD
Trifluoperazine—Agitation—Losartan—type 2 diabetes mellitus	0.000113	0.000903	CcSEcCtD
Trifluoperazine—Angioedema—Losartan—type 2 diabetes mellitus	0.000113	0.000898	CcSEcCtD
Trifluoperazine—Insomnia—Valsartan—type 2 diabetes mellitus	0.000112	0.000897	CcSEcCtD
Trifluoperazine—Insomnia—Orlistat—type 2 diabetes mellitus	0.000111	0.000887	CcSEcCtD
Trifluoperazine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000111	0.000886	CcSEcCtD
Trifluoperazine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000111	0.000884	CcSEcCtD
Trifluoperazine—Somnolence—Valsartan—type 2 diabetes mellitus	0.00011	0.000882	CcSEcCtD
Trifluoperazine—Leukopenia—Losartan—type 2 diabetes mellitus	0.00011	0.00088	CcSEcCtD
Trifluoperazine—Skin disorder—Metformin—type 2 diabetes mellitus	0.00011	0.000877	CcSEcCtD
Trifluoperazine—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000109	0.00211	CbGeAlD
Trifluoperazine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000109	0.00087	CcSEcCtD
Trifluoperazine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000109	0.00087	CcSEcCtD
Trifluoperazine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000108	0.000866	CcSEcCtD
Trifluoperazine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000108	0.000863	CcSEcCtD
Trifluoperazine—Asthenia—Glyburide—type 2 diabetes mellitus	0.000108	0.000863	CcSEcCtD
Trifluoperazine—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000108	0.000862	CcSEcCtD
Trifluoperazine—Anorexia—Metformin—type 2 diabetes mellitus	0.000108	0.000861	CcSEcCtD
Trifluoperazine—Cough—Losartan—type 2 diabetes mellitus	0.000107	0.000858	CcSEcCtD
Trifluoperazine—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000107	0.000858	CcSEcCtD
Trifluoperazine—Fatigue—Valsartan—type 2 diabetes mellitus	0.000107	0.000855	CcSEcCtD
Trifluoperazine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000107	0.000854	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000107	0.000853	CcSEcCtD
Trifluoperazine—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000107	0.000852	CcSEcCtD
Trifluoperazine—Pruritus—Glyburide—type 2 diabetes mellitus	0.000107	0.000851	CcSEcCtD
Trifluoperazine—Constipation—Valsartan—type 2 diabetes mellitus	0.000106	0.000848	CcSEcCtD
Trifluoperazine—Fatigue—Orlistat—type 2 diabetes mellitus	0.000106	0.000845	CcSEcCtD
Trifluoperazine—Hypotension—Metformin—type 2 diabetes mellitus	0.000106	0.000844	CcSEcCtD
Trifluoperazine—Erythema—Ramipril—type 2 diabetes mellitus	0.000106	0.000843	CcSEcCtD
Trifluoperazine—Rash—Bromocriptine—type 2 diabetes mellitus	0.000104	0.000829	CcSEcCtD
Trifluoperazine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000104	0.000829	CcSEcCtD
Trifluoperazine—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000104	0.000828	CcSEcCtD
Trifluoperazine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000103	0.000824	CcSEcCtD
Trifluoperazine—Nervousness—Ramipril—type 2 diabetes mellitus	0.000103	0.000819	CcSEcCtD
Trifluoperazine—Dry mouth—Losartan—type 2 diabetes mellitus	0.000103	0.000819	CcSEcCtD
Trifluoperazine—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000102	0.000813	CcSEcCtD
Trifluoperazine—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000102	0.00081	CcSEcCtD
Trifluoperazine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000101	0.000805	CcSEcCtD
Trifluoperazine—Somnolence—Metformin—type 2 diabetes mellitus	0.000101	0.000803	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.0001	0.000802	CcSEcCtD
Trifluoperazine—Hypotension—Irbesartan—type 2 diabetes mellitus	9.98e-05	0.000797	CcSEcCtD
Trifluoperazine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	9.96e-05	0.000796	CcSEcCtD
Trifluoperazine—Tremor—Ramipril—type 2 diabetes mellitus	9.89e-05	0.00079	CcSEcCtD
Trifluoperazine—Urticaria—Valsartan—type 2 diabetes mellitus	9.87e-05	0.000788	CcSEcCtD
Trifluoperazine—Decreased appetite—Metformin—type 2 diabetes mellitus	9.84e-05	0.000785	CcSEcCtD
Trifluoperazine—Nausea—Bromocriptine—type 2 diabetes mellitus	9.79e-05	0.000781	CcSEcCtD
Trifluoperazine—Fatigue—Metformin—type 2 diabetes mellitus	9.76e-05	0.000779	CcSEcCtD
Trifluoperazine—Urticaria—Orlistat—type 2 diabetes mellitus	9.75e-05	0.000779	CcSEcCtD
Trifluoperazine—Body temperature increased—Orlistat—type 2 diabetes mellitus	9.71e-05	0.000775	CcSEcCtD
Trifluoperazine—Asthenia—Gliclazide—type 2 diabetes mellitus	9.7e-05	0.000775	CcSEcCtD
Trifluoperazine—Agitation—Ramipril—type 2 diabetes mellitus	9.7e-05	0.000775	CcSEcCtD
Trifluoperazine—Constipation—Metformin—type 2 diabetes mellitus	9.68e-05	0.000773	CcSEcCtD
Trifluoperazine—Angioedema—Ramipril—type 2 diabetes mellitus	9.65e-05	0.00077	CcSEcCtD
Trifluoperazine—Anorexia—Losartan—type 2 diabetes mellitus	9.58e-05	0.000765	CcSEcCtD
Trifluoperazine—Pruritus—Gliclazide—type 2 diabetes mellitus	9.57e-05	0.000764	CcSEcCtD
Trifluoperazine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	9.52e-05	0.00076	CcSEcCtD
Trifluoperazine—Rash—Glyburide—type 2 diabetes mellitus	9.5e-05	0.000758	CcSEcCtD
Trifluoperazine—Somnolence—Irbesartan—type 2 diabetes mellitus	9.49e-05	0.000758	CcSEcCtD
Trifluoperazine—Dermatitis—Glyburide—type 2 diabetes mellitus	9.49e-05	0.000757	CcSEcCtD
Trifluoperazine—Leukopenia—Ramipril—type 2 diabetes mellitus	9.45e-05	0.000755	CcSEcCtD
Trifluoperazine—Headache—Glyburide—type 2 diabetes mellitus	9.44e-05	0.000753	CcSEcCtD
Trifluoperazine—Hypotension—Losartan—type 2 diabetes mellitus	9.39e-05	0.00075	CcSEcCtD
Trifluoperazine—Chlorpromazine—CALM1—type 2 diabetes mellitus	9.32e-05	0.0244	CrCbGaD
Trifluoperazine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	9.28e-05	0.000741	CcSEcCtD
Trifluoperazine—Cough—Ramipril—type 2 diabetes mellitus	9.21e-05	0.000736	CcSEcCtD
Trifluoperazine—Fatigue—Irbesartan—type 2 diabetes mellitus	9.21e-05	0.000735	CcSEcCtD
Trifluoperazine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	9.15e-05	0.000731	CcSEcCtD
Trifluoperazine—Convulsion—Ramipril—type 2 diabetes mellitus	9.15e-05	0.00073	CcSEcCtD
Trifluoperazine—Constipation—Irbesartan—type 2 diabetes mellitus	9.13e-05	0.000729	CcSEcCtD
Trifluoperazine—Insomnia—Losartan—type 2 diabetes mellitus	9.09e-05	0.000726	CcSEcCtD
Trifluoperazine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	9.05e-05	0.000722	CcSEcCtD
Trifluoperazine—Zuclopenthixol—ADRA2A—type 2 diabetes mellitus	9.02e-05	0.0236	CrCbGaD
Trifluoperazine—Urticaria—Metformin—type 2 diabetes mellitus	8.99e-05	0.000718	CcSEcCtD
Trifluoperazine—Nefazodone—ADRA2A—type 2 diabetes mellitus	8.97e-05	0.0235	CrCbGaD
Trifluoperazine—Dyspnoea—Losartan—type 2 diabetes mellitus	8.96e-05	0.000715	CcSEcCtD
Trifluoperazine—Nausea—Glyburide—type 2 diabetes mellitus	8.95e-05	0.000714	CcSEcCtD
Trifluoperazine—Dizziness—Gliclazide—type 2 diabetes mellitus	8.94e-05	0.000714	CcSEcCtD
Trifluoperazine—Somnolence—Losartan—type 2 diabetes mellitus	8.93e-05	0.000713	CcSEcCtD
Trifluoperazine—Asthenia—Valsartan—type 2 diabetes mellitus	8.91e-05	0.000712	CcSEcCtD
Trifluoperazine—Asthenia—Orlistat—type 2 diabetes mellitus	8.81e-05	0.000703	CcSEcCtD
Trifluoperazine—Pruritus—Valsartan—type 2 diabetes mellitus	8.79e-05	0.000702	CcSEcCtD
Trifluoperazine—Dry mouth—Ramipril—type 2 diabetes mellitus	8.79e-05	0.000702	CcSEcCtD
Trifluoperazine—Decreased appetite—Losartan—type 2 diabetes mellitus	8.74e-05	0.000697	CcSEcCtD
Trifluoperazine—Pruritus—Orlistat—type 2 diabetes mellitus	8.69e-05	0.000694	CcSEcCtD
Trifluoperazine—Fatigue—Losartan—type 2 diabetes mellitus	8.66e-05	0.000692	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	8.62e-05	0.000688	CcSEcCtD
Trifluoperazine—Constipation—Losartan—type 2 diabetes mellitus	8.59e-05	0.000686	CcSEcCtD
Trifluoperazine—Rash—Gliclazide—type 2 diabetes mellitus	8.53e-05	0.000681	CcSEcCtD
Trifluoperazine—Dermatitis—Gliclazide—type 2 diabetes mellitus	8.52e-05	0.00068	CcSEcCtD
Trifluoperazine—Urticaria—Irbesartan—type 2 diabetes mellitus	8.48e-05	0.000677	CcSEcCtD
Trifluoperazine—Headache—Gliclazide—type 2 diabetes mellitus	8.47e-05	0.000676	CcSEcCtD
Trifluoperazine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	8.44e-05	0.000674	CcSEcCtD
Trifluoperazine—Skin disorder—Ramipril—type 2 diabetes mellitus	8.37e-05	0.000668	CcSEcCtD
Trifluoperazine—Trazodone—ADRA2A—type 2 diabetes mellitus	8.3e-05	0.0217	CrCbGaD
Trifluoperazine—Nefazodone—HTR2C—type 2 diabetes mellitus	8.26e-05	0.0216	CrCbGaD
Trifluoperazine—Dizziness—Valsartan—type 2 diabetes mellitus	8.22e-05	0.000656	CcSEcCtD
Trifluoperazine—Anorexia—Ramipril—type 2 diabetes mellitus	8.21e-05	0.000656	CcSEcCtD
Trifluoperazine—Dizziness—Orlistat—type 2 diabetes mellitus	8.12e-05	0.000648	CcSEcCtD
Trifluoperazine—Asthenia—Metformin—type 2 diabetes mellitus	8.12e-05	0.000648	CcSEcCtD
Trifluoperazine—Hypotension—Ramipril—type 2 diabetes mellitus	8.05e-05	0.000643	CcSEcCtD
Trifluoperazine—Nausea—Gliclazide—type 2 diabetes mellitus	8.03e-05	0.000641	CcSEcCtD
Trifluoperazine—Pruritus—Metformin—type 2 diabetes mellitus	8.01e-05	0.000639	CcSEcCtD
Trifluoperazine—Urticaria—Losartan—type 2 diabetes mellitus	7.98e-05	0.000637	CcSEcCtD
Trifluoperazine—Body temperature increased—Losartan—type 2 diabetes mellitus	7.94e-05	0.000634	CcSEcCtD
Trifluoperazine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	7.87e-05	0.000628	CcSEcCtD
Trifluoperazine—Rash—Valsartan—type 2 diabetes mellitus	7.83e-05	0.000625	CcSEcCtD
Trifluoperazine—Dermatitis—Valsartan—type 2 diabetes mellitus	7.83e-05	0.000625	CcSEcCtD
Trifluoperazine—Insomnia—Ramipril—type 2 diabetes mellitus	7.79e-05	0.000622	CcSEcCtD
Trifluoperazine—Headache—Valsartan—type 2 diabetes mellitus	7.78e-05	0.000621	CcSEcCtD
Trifluoperazine—Thiothixene—ADRA2A—type 2 diabetes mellitus	7.78e-05	0.0203	CrCbGaD
Trifluoperazine—Rash—Orlistat—type 2 diabetes mellitus	7.74e-05	0.000618	CcSEcCtD
Trifluoperazine—Dermatitis—Orlistat—type 2 diabetes mellitus	7.73e-05	0.000617	CcSEcCtD
Trifluoperazine—Headache—Orlistat—type 2 diabetes mellitus	7.69e-05	0.000614	CcSEcCtD
Trifluoperazine—Dyspnoea—Ramipril—type 2 diabetes mellitus	7.68e-05	0.000613	CcSEcCtD
Trifluoperazine—Asthenia—Irbesartan—type 2 diabetes mellitus	7.66e-05	0.000612	CcSEcCtD
Trifluoperazine—Somnolence—Ramipril—type 2 diabetes mellitus	7.66e-05	0.000612	CcSEcCtD
Trifluoperazine—ABCB1—liver—type 2 diabetes mellitus	7.64e-05	0.00148	CbGeAlD
Trifluoperazine—Trazodone—HTR2C—type 2 diabetes mellitus	7.64e-05	0.02	CrCbGaD
Trifluoperazine—Pruritus—Irbesartan—type 2 diabetes mellitus	7.55e-05	0.000603	CcSEcCtD
Trifluoperazine—Decreased appetite—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000598	CcSEcCtD
Trifluoperazine—Dizziness—Metformin—type 2 diabetes mellitus	7.48e-05	0.000597	CcSEcCtD
Trifluoperazine—Fatigue—Ramipril—type 2 diabetes mellitus	7.43e-05	0.000593	CcSEcCtD
Trifluoperazine—Hypersensitivity—Losartan—type 2 diabetes mellitus	7.4e-05	0.000591	CcSEcCtD
Trifluoperazine—Nausea—Valsartan—type 2 diabetes mellitus	7.38e-05	0.000589	CcSEcCtD
Trifluoperazine—Constipation—Ramipril—type 2 diabetes mellitus	7.37e-05	0.000588	CcSEcCtD
Trifluoperazine—Nausea—Orlistat—type 2 diabetes mellitus	7.29e-05	0.000582	CcSEcCtD
Trifluoperazine—Asthenia—Losartan—type 2 diabetes mellitus	7.21e-05	0.000576	CcSEcCtD
Trifluoperazine—Thiothixene—HTR2C—type 2 diabetes mellitus	7.16e-05	0.0187	CrCbGaD
Trifluoperazine—Rash—Metformin—type 2 diabetes mellitus	7.13e-05	0.00057	CcSEcCtD
Trifluoperazine—Dermatitis—Metformin—type 2 diabetes mellitus	7.13e-05	0.000569	CcSEcCtD
Trifluoperazine—Pruritus—Losartan—type 2 diabetes mellitus	7.11e-05	0.000568	CcSEcCtD
Trifluoperazine—Headache—Metformin—type 2 diabetes mellitus	7.09e-05	0.000566	CcSEcCtD
Trifluoperazine—Mesoridazine—HTR2C—type 2 diabetes mellitus	7.07e-05	0.0185	CrCbGaD
Trifluoperazine—Dizziness—Irbesartan—type 2 diabetes mellitus	7.06e-05	0.000564	CcSEcCtD
Trifluoperazine—Urticaria—Ramipril—type 2 diabetes mellitus	6.85e-05	0.000547	CcSEcCtD
Trifluoperazine—Prochlorperazine—HTR2C—type 2 diabetes mellitus	6.84e-05	0.0179	CrCbGaD
Trifluoperazine—Body temperature increased—Ramipril—type 2 diabetes mellitus	6.81e-05	0.000544	CcSEcCtD
Trifluoperazine—Rash—Irbesartan—type 2 diabetes mellitus	6.73e-05	0.000538	CcSEcCtD
Trifluoperazine—Dermatitis—Irbesartan—type 2 diabetes mellitus	6.73e-05	0.000537	CcSEcCtD
Trifluoperazine—Fluphenazine—ADRA2A—type 2 diabetes mellitus	6.72e-05	0.0176	CrCbGaD
Trifluoperazine—Nausea—Metformin—type 2 diabetes mellitus	6.72e-05	0.000537	CcSEcCtD
Trifluoperazine—Headache—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.000534	CcSEcCtD
Trifluoperazine—Dizziness—Losartan—type 2 diabetes mellitus	6.65e-05	0.000531	CcSEcCtD
Trifluoperazine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	6.35e-05	0.000507	CcSEcCtD
Trifluoperazine—Nausea—Irbesartan—type 2 diabetes mellitus	6.34e-05	0.000506	CcSEcCtD
Trifluoperazine—Rash—Losartan—type 2 diabetes mellitus	6.34e-05	0.000506	CcSEcCtD
Trifluoperazine—Dermatitis—Losartan—type 2 diabetes mellitus	6.33e-05	0.000505	CcSEcCtD
Trifluoperazine—Headache—Losartan—type 2 diabetes mellitus	6.3e-05	0.000503	CcSEcCtD
Trifluoperazine—Fluphenazine—HTR2C—type 2 diabetes mellitus	6.19e-05	0.0162	CrCbGaD
Trifluoperazine—Asthenia—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000494	CcSEcCtD
Trifluoperazine—Clomipramine—ADRA2A—type 2 diabetes mellitus	6.15e-05	0.0161	CrCbGaD
Trifluoperazine—Pruritus—Ramipril—type 2 diabetes mellitus	6.1e-05	0.000487	CcSEcCtD
Trifluoperazine—Nausea—Losartan—type 2 diabetes mellitus	5.97e-05	0.000477	CcSEcCtD
Trifluoperazine—Propiomazine—HTR2C—type 2 diabetes mellitus	5.95e-05	0.0156	CrCbGaD
Trifluoperazine—Alimemazine—CYP3A4—type 2 diabetes mellitus	5.84e-05	0.0153	CrCbGaD
Trifluoperazine—Thioridazine—ADRA2A—type 2 diabetes mellitus	5.79e-05	0.0151	CrCbGaD
Trifluoperazine—Dizziness—Ramipril—type 2 diabetes mellitus	5.7e-05	0.000455	CcSEcCtD
Trifluoperazine—Clomipramine—HTR2C—type 2 diabetes mellitus	5.66e-05	0.0148	CrCbGaD
Trifluoperazine—Methotrimeprazine—ADRA2A—type 2 diabetes mellitus	5.53e-05	0.0145	CrCbGaD
Trifluoperazine—Rash—Ramipril—type 2 diabetes mellitus	5.43e-05	0.000434	CcSEcCtD
Trifluoperazine—Dermatitis—Ramipril—type 2 diabetes mellitus	5.43e-05	0.000433	CcSEcCtD
Trifluoperazine—Pipotiazine—CYP1A2—type 2 diabetes mellitus	5.4e-05	0.0141	CrCbGaD
Trifluoperazine—Thiothixene—CYP1A2—type 2 diabetes mellitus	5.4e-05	0.0141	CrCbGaD
Trifluoperazine—Headache—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000431	CcSEcCtD
Trifluoperazine—Loxapine—ADRA2A—type 2 diabetes mellitus	5.34e-05	0.014	CrCbGaD
Trifluoperazine—Thioridazine—HTR2C—type 2 diabetes mellitus	5.33e-05	0.0139	CrCbGaD
Trifluoperazine—Perphenazine—ADRA2A—type 2 diabetes mellitus	5.32e-05	0.0139	CrCbGaD
Trifluoperazine—Quetiapine—ADRA2A—type 2 diabetes mellitus	5.21e-05	0.0136	CrCbGaD
Trifluoperazine—Nausea—Ramipril—type 2 diabetes mellitus	5.12e-05	0.000409	CcSEcCtD
Trifluoperazine—Methotrimeprazine—HTR2C—type 2 diabetes mellitus	5.09e-05	0.0133	CrCbGaD
Trifluoperazine—Mequitazine—CYP3A4—type 2 diabetes mellitus	5.03e-05	0.0132	CrCbGaD
Trifluoperazine—Loxapine—HTR2C—type 2 diabetes mellitus	4.92e-05	0.0129	CrCbGaD
Trifluoperazine—Fluphenazine—CYP2E1—type 2 diabetes mellitus	4.91e-05	0.0128	CrCbGaD
Trifluoperazine—Perphenazine—HTR2C—type 2 diabetes mellitus	4.89e-05	0.0128	CrCbGaD
Trifluoperazine—Quetiapine—HTR2C—type 2 diabetes mellitus	4.8e-05	0.0126	CrCbGaD
Trifluoperazine—Promazine—ADRA2A—type 2 diabetes mellitus	4.79e-05	0.0125	CrCbGaD
Trifluoperazine—Fluphenazine—CYP1A2—type 2 diabetes mellitus	4.67e-05	0.0122	CrCbGaD
Trifluoperazine—Clozapine—ADRA2A—type 2 diabetes mellitus	4.48e-05	0.0117	CrCbGaD
Trifluoperazine—Promazine—HTR2C—type 2 diabetes mellitus	4.41e-05	0.0115	CrCbGaD
Trifluoperazine—Clomipramine—CYP1A2—type 2 diabetes mellitus	4.27e-05	0.0112	CrCbGaD
Trifluoperazine—Thioridazine—CYP2E1—type 2 diabetes mellitus	4.23e-05	0.0111	CrCbGaD
Trifluoperazine—Chlorpromazine—ADRA2A—type 2 diabetes mellitus	4.22e-05	0.011	CrCbGaD
Trifluoperazine—Clozapine—HTR2C—type 2 diabetes mellitus	4.13e-05	0.0108	CrCbGaD
Trifluoperazine—Nefazodone—CYP3A4—type 2 diabetes mellitus	4.13e-05	0.0108	CrCbGaD
Trifluoperazine—Methotrimeprazine—CYP2E1—type 2 diabetes mellitus	4.04e-05	0.0106	CrCbGaD
Trifluoperazine—Thioridazine—CYP1A2—type 2 diabetes mellitus	4.02e-05	0.0105	CrCbGaD
Trifluoperazine—Chlorpromazine—HTR2C—type 2 diabetes mellitus	3.88e-05	0.0102	CrCbGaD
Trifluoperazine—Methotrimeprazine—CYP1A2—type 2 diabetes mellitus	3.84e-05	0.01	CrCbGaD
Trifluoperazine—Trazodone—CYP3A4—type 2 diabetes mellitus	3.82e-05	0.00998	CrCbGaD
Trifluoperazine—Perphenazine—CYP1A2—type 2 diabetes mellitus	3.69e-05	0.00966	CrCbGaD
Trifluoperazine—Pipotiazine—CYP3A4—type 2 diabetes mellitus	3.58e-05	0.00936	CrCbGaD
Trifluoperazine—Prochlorperazine—CYP3A4—type 2 diabetes mellitus	3.42e-05	0.00894	CrCbGaD
Trifluoperazine—Promazine—CYP1A2—type 2 diabetes mellitus	3.33e-05	0.00871	CrCbGaD
Trifluoperazine—Clozapine—CYP2E1—type 2 diabetes mellitus	3.27e-05	0.00856	CrCbGaD
Trifluoperazine—Acepromazine—ALB—type 2 diabetes mellitus	3.24e-05	0.00849	CrCbGaD
Trifluoperazine—Thioproperazine—ALB—type 2 diabetes mellitus	3.17e-05	0.0083	CrCbGaD
Trifluoperazine—Thiothixene—ALB—type 2 diabetes mellitus	3.12e-05	0.00816	CrCbGaD
Trifluoperazine—Pipotiazine—ALB—type 2 diabetes mellitus	3.12e-05	0.00816	CrCbGaD
Trifluoperazine—Clozapine—CYP1A2—type 2 diabetes mellitus	3.11e-05	0.00815	CrCbGaD
Trifluoperazine—Chlorpromazine—CYP2E1—type 2 diabetes mellitus	3.08e-05	0.00805	CrCbGaD
Trifluoperazine—Chlorpromazine—CYP1A2—type 2 diabetes mellitus	2.93e-05	0.00766	CrCbGaD
Trifluoperazine—Clomipramine—CYP3A4—type 2 diabetes mellitus	2.83e-05	0.0074	CrCbGaD
Trifluoperazine—Clomipramine—ALB—type 2 diabetes mellitus	2.47e-05	0.00645	CrCbGaD
Trifluoperazine—Perphenazine—CYP3A4—type 2 diabetes mellitus	2.44e-05	0.00639	CrCbGaD
Trifluoperazine—Quetiapine—CYP3A4—type 2 diabetes mellitus	2.4e-05	0.00627	CrCbGaD
Trifluoperazine—Promazine—CYP3A4—type 2 diabetes mellitus	2.2e-05	0.00576	CrCbGaD
Trifluoperazine—Clozapine—CYP3A4—type 2 diabetes mellitus	2.06e-05	0.00539	CrCbGaD
Trifluoperazine—Chlorpromazine—CYP3A4—type 2 diabetes mellitus	1.94e-05	0.00507	CrCbGaD
Trifluoperazine—Chlorpromazine—ALB—type 2 diabetes mellitus	1.69e-05	0.00442	CrCbGaD
Trifluoperazine—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.61e-06	1.54e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.6e-06	1.53e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.6e-06	1.53e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—NFKB1—type 2 diabetes mellitus	1.59e-06	1.52e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.59e-06	1.52e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.59e-06	1.52e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.59e-06	1.52e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—AKT1—type 2 diabetes mellitus	1.59e-06	1.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.58e-06	1.51e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.58e-06	1.51e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.58e-06	1.51e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.57e-06	1.5e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—ALB—type 2 diabetes mellitus	1.57e-06	1.5e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—ALB—type 2 diabetes mellitus	1.57e-06	1.5e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.57e-06	1.5e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.56e-06	1.49e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.56e-06	1.49e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.56e-06	1.49e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.56e-06	1.49e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PIK3R1—type 2 diabetes mellitus	1.55e-06	1.48e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—NOS3—type 2 diabetes mellitus	1.55e-06	1.48e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.55e-06	1.48e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.55e-06	1.48e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.55e-06	1.48e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.54e-06	1.47e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—NFKB1—type 2 diabetes mellitus	1.54e-06	1.47e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—NFKB1—type 2 diabetes mellitus	1.54e-06	1.47e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.54e-06	1.47e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.54e-06	1.47e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.54e-06	1.47e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—AKT1—type 2 diabetes mellitus	1.53e-06	1.46e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—AKT1—type 2 diabetes mellitus	1.53e-06	1.46e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.53e-06	1.46e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.53e-06	1.46e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.53e-06	1.46e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.53e-06	1.46e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.52e-06	1.46e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.52e-06	1.45e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.52e-06	1.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—NOS3—type 2 diabetes mellitus	1.5e-06	1.44e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.5e-06	1.44e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—NOS3—type 2 diabetes mellitus	1.5e-06	1.44e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.5e-06	1.44e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.5e-06	1.43e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.5e-06	1.43e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.5e-06	1.43e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.5e-06	1.43e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—SRC—type 2 diabetes mellitus	1.49e-06	1.42e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—INS—type 2 diabetes mellitus	1.48e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.47e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.47e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.47e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.47e-06	1.4e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.47e-06	1.4e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1.46e-06	1.39e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.46e-06	1.39e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.45e-06	1.39e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.45e-06	1.38e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.45e-06	1.38e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.44e-06	1.38e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.44e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—SRC—type 2 diabetes mellitus	1.44e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—SRC—type 2 diabetes mellitus	1.44e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—INS—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—INS—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.43e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.42e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PTGS2—type 2 diabetes mellitus	1.42e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.41e-06	1.35e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.41e-06	1.35e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.41e-06	1.35e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.39e-06	1.32e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.39e-06	1.32e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTGS2—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTGS2—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—SRC—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.35e-06	1.29e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	1.35e-06	1.29e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—SRC—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—SRC—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.31e-06	1.25e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.3e-06	1.25e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.3e-06	1.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—EGFR—type 2 diabetes mellitus	1.3e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.3e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.3e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.3e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.3e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.3e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.29e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.28e-06	1.22e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.28e-06	1.22e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.26e-06	1.21e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—EGFR—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—EGFR—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.25e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.25e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.24e-06	1.19e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1.24e-06	1.18e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.24e-06	1.18e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.24e-06	1.18e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.23e-06	1.18e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.23e-06	1.18e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.23e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—TGFB1—type 2 diabetes mellitus	1.23e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—RELA—type 2 diabetes mellitus	1.22e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.22e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	1.22e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.22e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.22e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.22e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EGFR—type 2 diabetes mellitus	1.2e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.2e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.2e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.19e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.19e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—TGFB1—type 2 diabetes mellitus	1.19e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—TGFB1—type 2 diabetes mellitus	1.19e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.18e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.18e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.18e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.18e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.18e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.17e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.17e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EGFR—type 2 diabetes mellitus	1.16e-06	1.11e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EGFR—type 2 diabetes mellitus	1.16e-06	1.11e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.16e-06	1.11e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.16e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.15e-06	1.09e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.14e-06	1.09e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.13e-06	1.08e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.13e-06	1.08e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.12e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.12e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.11e-06	1.06e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.1e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.1e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.1e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	1.09e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.08e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	1.07e-06	1.02e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.07e-06	1.02e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.07e-06	1.02e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.06e-06	1.01e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.06e-06	1.01e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.05e-06	1e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.04e-06	9.95e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.03e-06	9.88e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.03e-06	9.86e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.03e-06	9.85e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.03e-06	9.85e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.02e-06	9.7e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.01e-06	9.69e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.01e-06	9.68e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.01e-06	9.67e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.01e-06	9.65e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.01e-06	9.63e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.01e-06	9.63e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL6—type 2 diabetes mellitus	1e-06	9.56e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.97e-07	9.53e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.97e-07	9.53e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.96e-07	9.51e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.93e-07	9.49e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	9.83e-07	9.38e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.78e-07	9.34e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.78e-07	9.34e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL6—type 2 diabetes mellitus	9.68e-07	9.25e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL6—type 2 diabetes mellitus	9.68e-07	9.25e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—SRC—type 2 diabetes mellitus	9.61e-07	9.18e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	9.4e-07	8.98e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	9.4e-07	8.98e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.36e-07	8.94e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SRC—type 2 diabetes mellitus	9.29e-07	8.88e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SRC—type 2 diabetes mellitus	9.29e-07	8.88e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—IL6—type 2 diabetes mellitus	9.24e-07	8.83e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—AKT1—type 2 diabetes mellitus	9.24e-07	8.82e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.05e-07	8.65e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.05e-07	8.65e-06	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	9.03e-07	8.62e-06	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	8.98e-07	8.58e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—IL6—type 2 diabetes mellitus	8.94e-07	8.54e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—IL6—type 2 diabetes mellitus	8.94e-07	8.54e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—AKT1—type 2 diabetes mellitus	8.93e-07	8.53e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—AKT1—type 2 diabetes mellitus	8.93e-07	8.53e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	8.6e-07	8.21e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.59e-07	8.2e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—AKT1—type 2 diabetes mellitus	8.53e-07	8.14e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.42e-07	8.04e-06	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.33e-07	7.95e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.31e-07	7.94e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.31e-07	7.94e-06	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.28e-07	7.91e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—AKT1—type 2 diabetes mellitus	8.25e-07	7.88e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—AKT1—type 2 diabetes mellitus	8.25e-07	7.88e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.15e-07	7.78e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.15e-07	7.78e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	7.92e-07	7.57e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.8e-07	7.45e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	7.78e-07	7.43e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	7.66e-07	7.31e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.63e-07	7.29e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.31e-07	6.98e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.19e-07	6.87e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.18e-07	6.86e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—AKT1—type 2 diabetes mellitus	7.14e-07	6.82e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.06e-07	6.75e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.04e-07	6.73e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—AKT1—type 2 diabetes mellitus	6.91e-07	6.6e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—AKT1—type 2 diabetes mellitus	6.91e-07	6.6e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL6—type 2 diabetes mellitus	6.47e-07	6.18e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL6—type 2 diabetes mellitus	6.26e-07	5.98e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.26e-07	5.98e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.97e-07	5.7e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.78e-07	5.52e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.78e-07	5.52e-06	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	5.41e-07	5.17e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	4.32e-07	4.13e-06	CbGpPWpGaD
